Search | Clinical Trials Finder

Conditions: Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction
Interventions: HNO Donor, Nitroglycerin (NTG), Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Tustin, California • Chicago, Illinois • Indianapolis, Indiana + 3 more

Conditions: Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Minneapolis, Minnesota • Charlotte, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: Omecamtiv Mecarbil, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 36
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Torrance, California + 31 more

Conditions: Heart Failure
Interventions: AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor; Device
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: Powerbreathe; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: JK07, Matching Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Tucson, Arizona • Stanford, California • Boston, Massachusetts + 4 more

Conditions: Heart Failure
Interventions: Neladenoson bialanate (BAY1067197), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Naples, Florida • Detroit, Michigan • Jackson, Mississippi + 6 more

Conditions: Heart Failure, Systolic
Interventions: Dapagliflozin, CardioMEMS; Drug · Device
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Heart Failure With Reduced Ejection Fraction, Nonischemic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic
Interventions: VITARIA System; Device
Lead sponsor: LivaNova; Industry
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 19 more

Conditions: Acute Heart Failure
Interventions: 6 Minute Walk Test; Procedure
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Indianapolis, Indiana • Detroit, Michigan • Winston-Salem, North Carolina + 2 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions: Tovinontrine (CRD-750), Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure, Systolic, Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
Interventions: Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Walnut Creek, California • Aurora, Colorado • New Haven, Connecticut + 2 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Josef Stehlik; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction
Interventions: Not listed
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more

Conditions: Heart Failure
Interventions: Omecamtiv Mecarbil, Placebo, Standard of Care; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 310
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more

Conditions: Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction, LVAD
Interventions: Exposure of interest - Use of left ventricular assist device (LVAD); Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions: Dobutamine, Amlodipine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: ketone ester, placebo; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Heart Failure
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 3,730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 92
States / cities: La Mesa, California • Long Beach, California • Los Angeles, California + 81 more

Conditions: Heart Failure, Reduced Ejection Fraction
Interventions: sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more

Conditions: Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
Interventions: Cardiopulmonary exercise test, Echocardiogram; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 110 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

REALIsM-HF Pilot Study

A Study Investigating the Impact of IMT With CR On Exercise Responses In HF

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

Gut Microbiome Profiling in Patients With Chronic Heart Failure

ANTHEM-HFrEF Pivotal Study

An Observational Study of the Functional Capacity of Heart Failure

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

Pilot Study Lp299v Supplementation in Chronic Heart Failure

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

LYmphangiogenesis FacTors in Heart Failure States

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Endothelial Function in Mechanical Circulatory Support

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Ketones in Heart Failure With Reduced Ejection Fraction

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)